Aquestive Therapeutics (AQST) Capital Leases (2023 - 2025)

Aquestive Therapeutics' Capital Leases history runs 3 years deep, the most recent figure standing at $122000.0 for Q3 2025.

• In Q3 2025, Capital Leases fell 20.26% year-over-year to $122000.0; the TTM figure through Sep 2025 stood at $122000.0 (down 20.26% YoY), while the FY2024 annual figure was $146000.0, down 15.61% from the prior year.
• Capital Leases was $122000.0 for Q3 2025 at Aquestive Therapeutics, down from $130000.0 in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $173000.0 in Q4 2023 to a low of $122000.0 in Q3 2025.
• Historically, Capital Leases has averaged $148625.0 across 3 years, with a median of $149500.0 in 2024.
• The sharpest annual moves came in 2024 and 2025: Capital Leases retreated 15.61% in 2024, then retreated 20.26% in 2025.
• A 3-year view of Capital Leases shows it stood at $173000.0 in 2023, then slipped by 15.61% to $146000.0 in 2024, then dropped by 16.44% to $122000.0 in 2025.
• The last three Capital Leases figures came in at $122000.0 (Q3 2025), $130000.0 (Q2 2025), and $138000.0 (Q1 2025), per Business Quant data.